,Unnamed: 0,Unnamed: 0.1,Drug,Chemical Structure,Adverse Effect / Toxicity,Species,Dose,Dose Type,Route,Source,Source Link,Year
0,0,0,Abacavir Sulfate,NC1=NC(NC2CC2)=C2N=CN(C3C=CC(CO)C3)C2=N1,Hepatic necrosis,Mouse,-3.0,Repeated,Oral,"FDA approval package document: Pharmacology Review 020977/S-000; 020978/S-000 Part 01, page:14 PDF 1163k",https://www.pharmapendium.com/browse/fda/Abacavir Sulfate/07c4f5b0213d6bee80ea94c6175056dd?reference=14,1998.0
1,1,2,Acalabrutinib,CC#CC(=O)N1CCCC1C1=NC(C2=CC=C(C(=O)NC3=NC=CC=C3)C=C2)=C2C(N)=NC=CN12,Hepatic necrosis,Rat,-2.263241434774581,Repeated,Oral,"FDA approval package document: Approval Package 210259/S-000 Part 03, page:14 PDF 1302k",https://www.pharmapendium.com/browse/fda/Acalabrutinib/633aa3ab47963d58cef38988b8d98011?reference=14,2017.0
2,2,8,Acetaminophen,CC(=O)NC1=CC=C(O)C=C1,Hepatic necrosis,Rat,-1.81424759573192,Repeated,Oral,"Reference from PharmaPendium Published Toxicity: Toxicology 243,261,2008   ---   DOI:10.1016/J.TOX.2007.10.010   ISSN:0300-483X   JOURNAL:Toxicology   PAGES:261   VOLUME:243",http://dx.doi.org/10.1016/J.TOX.2007.10.010,2008.0
3,3,19,Adefovir Dipivoxil,CC(C)(C)C(=O)OCOP(=O)(COCCN1C=NC2=C1N=CN=C2N)OCOC(=O)C(C)(C)C,Hepatic necrosis,Mouse,-1.740362689494244,Repeated,Oral,"EMA approval document: Scientific Discussion, page:6 PDF 374k",https://www.pharmapendium.com/browse/ema/Adefovir Dipivoxil/00d5380517af7603a60129c3620b05dd?reference=6,2005.0
4,4,23,Ademetionine,C[S+](CCC(N)C(=O)[O-])CC1OC(N2C=NC3=C2N=CN=C3N)C(O)C1O,Hepatic necrosis,Rat,-0.6989700043360189,Repeated,Intravenous,Reference from PharmaPendium Published Toxicity: 363141496   ---   ISSN:0869-2092   JOURNAL:Eksperimental'naya i Klinicheskaya Farmakologiya   PAGES:34   VOLUME:74,,2011.0
5,5,24,Alcohol,CCO,Hepatic necrosis,Mouse,-4.547313099163422,Repeated,Oral,"Reference from PharmaPendium Published Toxicity: Fundamental & Clinical Pharmacology (Oxford: Blackwell Science) 20,129,2006   ---   DOI:10.1111/j.1472-8206.2006.00403.x   JOURNAL:Fundamental and Clinical Pharmacology   PAGES:129   VOLUME:20",http://dx.doi.org/10.1111/j.1472-8206.2006.00403.x,2006.0
6,6,28,Almotriptan Malate,CN(C)CCC1=CNC2=C1C=C(CS(=O)(=O)N1CCCC1)C=C2,Hepatic necrosis,Rat,-2.6989700043360187,Repeated,Oral,"FDA approval package document: Pharmacology Review 021001/S-000 Part 01, page:54 PDF 1950k",https://www.pharmapendium.com/browse/fda/Almotriptan Malate/65a4fd1f91a6b2d9de68e8285c53b339?reference=54,1997.0
7,7,29,Ambrisentan,COC(C1=CC=CC=C1)(C1=CC=CC=C1)C(OC1=NC(C)=CC(C)=N1)C(=O)O,Hepatic necrosis,Mouse,-3.096910013008056,Repeated,Oral,"FDA approval package document: Pharmacology Review 022081/S-000 Part 03, page:7 PDF 5685k",https://www.pharmapendium.com/browse/fda/Ambrisentan/4d5aedf3fe04b0fe6c56247da78848e0?reference=7,2003.0
8,8,30,Amiodarone Hydrochloride,CCCCC1=C(C(=O)C2=CC(I)=C(OCCN(CC)CC)C(I)=C2)C2=CC=CC=C2O1,Hepatic necrosis,Rabbit,-0.6989700043360189,Repeated,Intravenous,"FDA approval package document: Pharmacology Review 018972/S-000, page:14 PDF 996k",https://www.pharmapendium.com/browse/fda/Amiodarone Hydrochloride/a2e7d5800e73b2dc238d09986b3c0842?reference=14,1984.0
9,10,33,Amphotericin B,CC1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/C(OC2OC(C)C(O)C(N)C2O)CC2OC(O)(CC(O)CC(O)C(O)CCC(O)CC(O)CC(=O)OC(C)C(C)C1O)CC(O)C2C(=O)O,Hepatic necrosis,Rat,-0.5797835966168101,Repeated,Intravenous,"FDA approval package document: Approval Package 050729 Part 02, page:53 PDF 6642k",https://www.pharmapendium.com/browse/fda/Amphotericin B/ad639acfa8d84a8cdfea4b238405c9c0?reference=53,1996.0
10,12,40,Amprenavir,CC(C)CN(CC(O)C(CC1=CC=CC=C1)NC(=O)OC1CCOC1)S(=O)(=O)C1=CC=C(N)C=C1,Hepatic necrosis,Rat,-2.278753600952829,Repeated,Oral,"FDA approval package document: Pharmacology Review 021007/S-000; 021039/S-000, page:19 PDF 1550k",https://www.pharmapendium.com/browse/fda/Amprenavir/48f67e7468197a28681d5099ab1d2aae?reference=19,1998.0
11,13,41,Anidulafungin,CCCCCOC1=CC=C(C2=CC=C(C3=CC=C(C(=O)NC4CC(O)C(O)NC(=O)C5C(O)C(C)CN5C(=O)C(C(C)O)NC(=O)C(C(O)C(O)C5=CC=C(O)C=C5)NC(=O)C5CC(O)CN5C(=O)C(C(C)O)NC4=O)C=C3)C=C2)C=C1,Hepatic necrosis,Rat,-1.3979400086720375,Repeated,Intravenous,"FDA approval package document: Pharmacology Review 021948/S-000; 021632/S-000, page:30 PDF 3419k",https://www.pharmapendium.com/browse/fda/Anidulafungin/5a8b3f5b87ca9a0caf47f2e7024cc485?reference=30,2003.0
12,14,43,Apixaban,COC1=CC=C(N2N=C(C(N)=O)C3=C2C(=O)N(C2=CC=C(N4CCCCC4=O)C=C2)CC3)C=C1,Hepatic necrosis,Mouse,-3.4771212547196626,Repeated,Oral,"FDA approval package document: Pharmacology Review 202155/S-000 Part 06, page:2 PDF 4834k",https://www.pharmapendium.com/browse/fda/Apixaban/72c74d11e807ac86fe3a61ae57b344d9?reference=2,2011.0
13,15,44,Apremilast,CCOC1=C(OC)C=CC(C(CS(C)(=O)=O)N2C(=O)C3=CC=CC(NC(C)=O)=C3C2=O)=C1,Hepatic necrosis,Mouse,-3.0,Repeated,Oral,"FDA approval package document: Pharmacology Review 205437/S-000 Part 04, page:24 PDF 15043k",https://www.pharmapendium.com/browse/fda/Apremilast/640f8cdc51359cc04d02fbdc43b32379?reference=24,2014.0
14,19,53,Armodafinil,NC(=O)C[S+]([O-])C(C1=CC=CC=C1)C1=CC=CC=C1,Hepatic necrosis,Rat,-2.3010299956639813,Repeated,Oral,"FDA approval package document: Pharmacology Review 021875/S-000, page:30 PDF 4896k",https://www.pharmapendium.com/browse/fda/Armodafinil/2021a1eaa664af7eee35442a36027c5f?reference=30,2006.0
15,20,54,Artesunate,CC1CCC2C(C)C(OC(=O)CCC(=O)O)OC3OC4(C)CCC1C32OO4,Hepatic necrosis,Rat,-1.6532125137753435,Repeated,Oral,Reference from PharmaPendium Published Toxicity: 602240407   ---   DOI:10.1016/j.toxrep.2015.01.007   ISSN:2214-7500   JOURNAL:Toxicology Reports   PAGES:280   VOLUME:2,http://dx.doi.org/10.1016/j.toxrep.2015.01.007,2015.0
16,22,56,Aspirin,CC(=O)OC1=CC=CC=C1C(=O)O,Hepatic necrosis,Rat,-1.4471580313422192,Repeated,Oral,Reference from PharmaPendium Published Toxicity: 52991863   ---   DOI:10.1016/j.biomag.2014.01.004   ISSN:2210-5220   JOURNAL:Biomedicine and Aging Pathology   PAGES:137   VOLUME:4,http://dx.doi.org/10.1016/j.biomag.2014.01.004,2014.0
17,23,57,Atazanavir Sulfate,COC(=O)NC(C(=O)NC(CC1=CC=CC=C1)C(O)CN(CC1=CC=C(C2=NC=CC=C2)C=C1)NC(=O)C(NC(=O)OC)C(C)(C)C)C(C)(C)C,Hepatic necrosis,Mouse,-2.2405492482826,Repeated,Oral,"Reference from PharmaPendium Published Toxicity: Toxicologist 44,363,2005   ---   ISSN:0731-9193   JOURNAL:Toxicologist   PAGES:363   VOLUME:44",,2005.0
18,24,60,Atropine Sulfate,CN1C2CCC1CC(OC(=O)C(CO)C1=CC=CC=C1)C2,Hepatic necrosis,Rat,-2.0791812460476247,Repeated,Intraperitoneal,Reference from PharmaPendium Published Toxicity: 362372038   ---   ISSN:1996-0875   JOURNAL:Journal of Medicinal Plant Research   PAGES:3421   VOLUME:5,,2011.0
19,26,63,Baricitinib,CCS(=O)(=O)N1CC(CC#N)(N2C=C(C3=C4C=CNC4=NC=N3)C=N2)C1,Hepatic necrosis,Mouse,-1.9590413923210936,Repeated,Oral,"FDA approval package document: Pharmacology Review 207924/S-000 Part 23, page:8 PDF 381k",https://www.pharmapendium.com/browse/fda/Baricitinib/11bacd65f5b48bf3a4448a1c8063e8ac?reference=8,2016.0
20,27,74,Bempedoic Acid,CC(C)(CCCCCC(O)CCCCCC(C)(C)C(=O)O)C(=O)O,Hepatic necrosis,Rat,-1.6532125137753435,Repeated,Oral,"FDA approval package document: Approval Package 211616/S-000 Part 08, page:22 PDF 849k",https://www.pharmapendium.com/browse/fda/Bempedoic Acid/ab62f621ee1b630854d8da3ece6dda69?reference=22,2019.0
21,31,88,Beta-Carotene,CC1=C(/C=C/C(C)=C/C=C/C(C)=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C2=C(C)CCCC2(C)C)C(C)(C)CCC1,Hepatic necrosis,Rat,-1.954242509439325,Repeated,Intragastric,Reference from PharmaPendium Published Toxicity: E-600218201   ---   DOI:10.1016/j.fct.2013.12.010   ISSN:0278-6915   JOURNAL:Food and Chemical Toxicology   PAGES:1   VOLUME:65,http://dx.doi.org/10.1016/j.fct.2013.12.010,2014.0
22,33,90,Bexarotene,C=C(C1=CC=C(C(=O)O)C=C1)C1=C(C)C=C2C(=C1)C(C)(C)CCC2(C)C,Hepatic necrosis,Rat,-1.3979400086720375,Repeated,Oral,"FDA approval package document: Pharmacology Review 021055/S-000 Part 02, page:19 PDF 979k",https://www.pharmapendium.com/browse/fda/Bexarotene/4912f11e6802d77025d4b6f313516222?reference=19,1999.0
23,35,98,Bivalirudin,CCC(C)C(NC(=O)C(CCC(=O)O)NC(=O)C(CCC(=O)O)NC(=O)C(CC1=CC=CC=C1)NC(=O)C(CC(=O)O)NC(=O)CNC(=O)C(CC(N)=O)NC(=O)CNC(=O)CNC(=O)CNC(=O)CNC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(N)CC1=CC=CC=C1)C(=O)N1CCCC1C(=O)NC(CCC(=O)O)C(=O)NC(CCC(=O)O)C(=O)NC(CC1=CC=C(O)C=C1)C(=O)NC(CC(C)C)C(=O)O,Hepatic necrosis,Rat,-2.282546589969968,Repeated,Intravenous,"FDA approval package document: Pharmacology Review 020873/S-000 Part 03, page:4 PDF 1408k",https://www.pharmapendium.com/browse/fda/Bivalirudin/41f60d987acb34b425c6a4e8b8f69a46?reference=4,1999.0
24,36,101,Bleomycin Sulfate,CC1=C(C(=O)NC(C(=O)NC(C)C(O)C(C)C(=O)NC(C(=O)NCCC2=NC(C3=NC=C(C(N)=O)S3)=CS2)C(C)O)C(OC2OC(CO)C(O)C(O)C2OC2OC(CO)C(O)C(OC(N)=O)C2O)C2=CNC=N2)N=C(C(CC(N)=O)NCC(N)C(N)=O)N=C1N,Hepatic necrosis,Rat,-0.7781512503836436,Repeated,Intraperitoneal,"FDA approval package document: Pharmacology Review 050443, page:10 PDF 876k",https://www.pharmapendium.com/browse/fda/Bleomycin Sulfate/c3f520917986d23020c92e1182560ad8?reference=10,1972.0
25,39,105,Butenafine Hydrochloride,CN(CC1=CC=C(C(C)(C)C)C=C1)CC1=CC=CC2=CC=CC=C12,Hepatic necrosis,Rat,-1.9030899869919435,Repeated,Oral,"FDA approval package document: Pharmacology Review 020524/S-005, page:5 PDF 399k",https://www.pharmapendium.com/browse/fda/Butenafine Hydrochloride/46b97c5aea2bd9e60954934697394239?reference=5,2000.0
26,40,108,Cabazitaxel,COC1=C2C(C)C(OC(=O)C(O)C(NC(=O)OC(C)(C)C)C3=CC=CC=C3)CC(O)(C(OC(=O)C3=CC=CC=C3)C3C4(OC(C)=O)COC4CC(OC)C3(C)C1=O)C2(C)C,Hepatic necrosis,Rat,-1.130333768495006,Repeated,Intravenous,"FDA approval package document: Pharmacology Review 201023/S-000 Part 11, page:53 PDF 993k",https://www.pharmapendium.com/browse/fda/Cabazitaxel/0838a00663962be87a997349054ed8b3?reference=53,2010.0
27,41,110,Cabergoline,C=CCN1CC(C(=O)N(CCCN(C)C)C(=O)NCC)CC2C3=CC=CC4=C3C(=CN4)CC21,Hepatic necrosis,Rat,-8.505149978319906,Repeated,Oral,"FDA approval package document: Approval Package 020664/S-000, page:17 PDF 6090k",https://www.pharmapendium.com/browse/fda/Cabergoline/ebf876563ad2f648a0171f18aab52dab?reference=17,1995.0
28,42,111,Calcitriol,C=C1/C(=C\C=C2/CCCC3(C)C2CCC3C(C)CCCC(C)(C)O)CC(O)CC1O,Hepatic necrosis,Rat,-6.845098040014257,Repeated,Skin,"FDA approval package document: Pharmacology Review 022087/S-000, page:43 PDF 7140k",https://www.pharmapendium.com/browse/fda/Calcitriol/5c0627c2590dd90e925f90b575fb6796?reference=43,2008.0
29,44,116,Carbamazepine,NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C21,Hepatic necrosis,Rat,-0.6989700043360189,Repeated,Oral,Reference from PharmaPendium Published Toxicity: 605769484   ---   DOI:10.1124/dmd.115.063370   ISSN:0090-9556   JOURNAL:Drug Metabolism and Disposition   PAGES:958   VOLUME:43,http://dx.doi.org/10.1124/dmd.115.063370,2015.0
30,45,117,Carfilzomib,CC(C)CC(NC(=O)C(CCC1=CC=CC=C1)NC(=O)CN1CCOCC1)C(=O)NC(CC1=CC=CC=C1)C(=O)NC(CC(C)C)C(=O)C1(C)CO1,Hepatic necrosis,Rat,-1.2787536009528289,Repeated,Intravenous,"FDA approval package document: Pharmacology Review 202714/S-000 Part 04, page:27 PDF 11026k",https://www.pharmapendium.com/browse/fda/Carfilzomib/1edacd3d842dc9102583efb676c8d26c?reference=27,2012.0
31,46,120,Carglumic Acid,NC(=O)NC(CCC(=O)O)C(=O)O,Hepatic necrosis,Rat,-3.0,Repeated,Oral,"FDA approval package document: Pharmacology Review 022562/S-000 Part 04, page:5 PDF 4470k",https://www.pharmapendium.com/browse/fda/Carglumic Acid/5715c822f5e5583890fe0d541762a880?reference=5,2010.0
32,48,132,Cefditoren Pivoxil,CON=C(C(=O)NC1C(=O)N2C(C(=O)OCOC(=O)C(C)(C)C)=C(/C=C\C3=C(C)N=CS3)CSC12)C1=CSC(N)=N1,Hepatic necrosis,Rat,-2.7781512503836434,Repeated,Oral,"FDA approval package document: Pharmacology Review 021222/S-000, page:7 PDF 1253k",https://www.pharmapendium.com/browse/fda/Cefditoren Pivoxil/0901a16bcd5765996b9634b7443f3eae?reference=7,1999.0
33,49,136,Cefixime,C=CC1=C(C(=O)O)N2C(=O)C(=NC(=O)C(NOCC(=O)O)C3=CSC(N)=N3)C2SC1,Hepatic necrosis,Rat,-2.0791812460476247,Repeated,Oral,Reference from PharmaPendium Published Toxicity: 2007991966   ---   DOI:10.36295/ASRO.2020.231389   ISSN:1755-6783   JOURNAL:Annals of Tropical Medicine and Public Health   PAGES:SP231389   VOLUME:23,http://dx.doi.org/10.36295/ASRO.2020.231389,2020.0
34,50,137,Ceftazidime,CC(C)(ON=C(C(=O)NC1C(=O)N2C(C(=O)[O-])=C(C[N+]3=CC=CC=C3)CSC12)C1=CSC(N)=N1)C(=O)O,Hepatic necrosis,Rat,-3.5642714304385628,Repeated,Subcutaneous,"FDA approval package document: Approval Package 050578 Part 01, page:15 PDF 4762k",https://www.pharmapendium.com/browse/fda/Ceftazidime/1cd0911cf52fca25f2dc0e6329639eec?reference=15,1985.0
35,59,158,Ciclopirox,CC1=CC(=O)N(O)C(C2CCCCC2)=C1,Hepatic necrosis,Rat,-1.6532125137753435,Repeated,Subcutaneous,"FDA approval package document: Approval Package 018748 Part 02, page:49 PDF 5723k",https://www.pharmapendium.com/browse/fda/Ciclopirox/16ef7e32e16afc74aacf281177b7d9ef?reference=49,1982.0
36,64,169,Clarithromycin,CCC1OC(=O)C(C)C(OC2CC(C)(OC)C(O)C(C)O2)C(C)C(OC2OC(C)CC(N(C)C)C2O)C(C)(OC)CC(C)C(=O)C(C)C(O)C1(C)O,Hepatic necrosis,Rat,-1.146128035678238,Repeated,Oral,Reference from PharmaPendium Published Toxicity: 368418603   ---   ISSN:0975-8232   JOURNAL:International Journal of Pharmaceutical Sciences and Research   PAGES:2623   VOLUME:3,,2012.0
37,70,178,Cocaine Hydrochloride,COC(=O)C1C(OC(=O)C2=CC=CC=C2)CC2CCC1N2C,Hepatic necrosis,Mouse,-0.9294189257142929,Repeated,Intraperitoneal,"Reference from PharmaPendium Published Toxicity: Experimental Biology and Medicine (Maywood, N.J.) 226,52,2001   ---   DOI:10.1177/153537020122600108   JOURNAL:Experimental Biology and Medicine   PAGES:52   VOLUME:226",http://dx.doi.org/10.1177/153537020122600108,2001.0
38,71,182,Colchicine,COC1=C(OC)C(OC)=C2C(=C1)CCC(NC(C)=O)C1=CC(=O)C(OC)=CC=C12,Hepatic necrosis,Rat,-0.7781512503836436,Repeated,Intragastric,Reference from PharmaPendium Published Toxicity: 362497867   ---   DOI:10.3969/j.issn.1001-1978.2011.07.030   ISSN:1001-1978   JOURNAL:Chinese Pharmacological Bulletin   PAGES:1019   VOLUME:27,http://dx.doi.org/10.3969/j.issn.1001-1978.2011.07.030,2011.0
39,73,186,Cyclosporine,C/C=C/CC(C)C(O)C1C(=O)NC(CC)C(=O)N(C)CC(=O)N(C)C(CC(C)C)C(=O)NC(C(C)C)C(=O)N(C)C(CC(C)C)C(=O)NC(C)C(=O)NC(C)C(=O)N(C)C(CC(C)C)C(=O)N(C)C(CC(C)C)C(=O)N(C)C(C(C)C)C(=O)N1C,Hepatic necrosis,Rat,-1.6101276130759954,Repeated,Oral,"FDA approval package document: Approval Package 050573 Part 05, page:24 PDF 4615k",https://www.pharmapendium.com/browse/fda/Cyclosporine/558cdf3c238a582a6fe3255577f2d5c4?reference=24,1987.0
40,75,191,Daclatasvir Dihydrochloride,COC(=O)NC(C(=O)N1CCCC1C1=NC(C2=CC=C(C3=CC=C(C4=CNC(C5CCCN5C(=O)C(NC(=O)OC)C(C)C)=N4)C=C3)C=C2)=CN1)C(C)C,Hepatic necrosis,Rat,-1.6989700043360187,Repeated,Oral,"FDA approval package document: Pharmacology Review 206843/S-000, page:52 PDF 12236k",https://www.pharmapendium.com/browse/fda/Daclatasvir Dihydrochloride/98806d898b2994892ff5c8abf1d109db?reference=52,2014.0
41,77,194,Darunavir Ethanolate,CC(C)CN(CC(O)C(CC1=CC=CC=C1)NC(=O)OC1COC2OCCC12)S(=O)(=O)C1=CC=C(N)C=C1,Hepatic necrosis,Mouse,-3.0,Repeated,Oral,"FDA approval package document: Pharmacology Review 021976/S-000, page:19 PDF 5798k",https://www.pharmapendium.com/browse/fda/Darunavir Ethanolate/70ef46cb4572329a480d6ccc4a1debe2?reference=19,2006.0
42,78,195,Deferasirox,O=C(O)C1=CC=C(N2N=C(C3=CC=CC=C3O)N=C2C2=CC=CC=C2O)C=C1,Hepatic necrosis,Mouse,-2.0,Repeated,Oral,"FDA approval package document: Pharmacology Review 021882/S-000 Part 02, page:13 PDF 2295k",https://www.pharmapendium.com/browse/fda/Deferasirox/5ff2b805ad7a0c471036bf8580b74b46?reference=13,2005.0
43,80,202,Delavirdine Mesylate,CC(C)NC1=CC=CN=C1N1CCN(C(=O)C2=CC3=C(C=CC(NS(C)(=O)=O)=C3)N2)CC1,Hepatic necrosis,Rat,-2.1760912590556813,Repeated,Oral,"FDA approval package document: Pharmacology Review 020705, page:4 PDF 1831k",https://www.pharmapendium.com/browse/fda/Delavirdine Mesylate/8ca8034d7edd97ba660b0908ff2e5d0f?reference=4,1996.0
44,86,219,Diltiazem Hydrochloride,COC1=CC=C(C2SC3=CC=CC=C3N(CCN(C)C)C(=O)C2OC(C)=O)C=C1,Hepatic necrosis,Mouse,-2.0,Repeated,Oral,"FDA approval package document: Pharmacology Review 020506 Part 02, page:6 PDF 887k",https://www.pharmapendium.com/browse/fda/Diltiazem Hydrochloride/ab39417b47fc9d43bce85a4bc8cd737f?reference=6,1995.0
45,87,221,Dimethyl Fumarate,COC(=O)/C=C/C(=O)OC,Hepatic necrosis,Rat,-2.0,Repeated,Oral,"EMA approval document: Assessment Report EMA/800904/2013; EMEA/H/C/002601/0000/Rev 1, page:22 PDF 6911k",https://www.pharmapendium.com/browse/ema/Dimethyl Fumarate/f1e215f3f688394efb5a7de33e8e61e1?reference=22,2013.0
46,88,224,Docetaxel,CC(=O)OC12COC1CC(O)C1(C)C(=O)C(=O)C3C(C)C(OC(=O)C(O)C(NC(=O)OC(C)(C)C)C4=CC=CC=C4)CC(O)(C(OC(=O)C4=CC=CC=C4)C21)C3(C)C,Hepatic necrosis,Mouse,-0.6989700043360189,Repeated,Intravenous,Reference from PharmaPendium Published Toxicity: 606105202   ---   DOI:10.1166/jbn.2015.2158   ISSN:1550-7033   JOURNAL:Journal of Biomedical Nanotechnology   PAGES:1747   VOLUME:11,http://dx.doi.org/10.1166/jbn.2015.2158,2015.0
47,89,225,Dolasetron Mesylate,O=C(OC1CC2CC3CC(C1)N2CC3=O)C1=CNC2=C1C=CC=C2,Hepatic necrosis,Mouse,-1.8750612633917,Repeated,Oral,"FDA approval package document: Pharmacology Review 020623/S-000 Part 02, page:18 PDF 1402k",https://www.pharmapendium.com/browse/fda/Dolasetron Mesylate/8d150bab9ee229d0369c58f736d44acf?reference=18,1996.0
48,90,227,Doxorubicin Hydrochloride,COC1=CC=CC2=C(O)C3=C(O)C4=CC(O)(C(=O)CO)CC(OC5CC(N)C(O)C(C)O5)=C4C(O)=C3C(O)=C12,Hepatic necrosis,Mouse,-1.0086001717619175,Repeated,Intraperitoneal,Reference from PharmaPendium Published Toxicity: 362795090   ---   ISSN:0030-9982   JOURNAL:Journal of the Pakistan Medical Association   PAGES:1108   VOLUME:61,,2011.0
49,91,233,Dronedarone Hydrochloride,CCCCC1=C(C(=O)C2=CC=C(OCCCN(CCCC)CCCC)C=C2)C2=CC(NS(C)(=O)=O)=CC=C2O1,Hepatic necrosis,Rat,-1.591064607026499,Repeated,Intravenous,"FDA approval package document: Pharmacology Review 022425/S-000 Part 02, page:134 PDF 3438k",https://www.pharmapendium.com/browse/fda/Dronedarone Hydrochloride/d8a13a7020f06e9ec9a3a334c32eeb45?reference=134,2009.0
50,96,244,Eletriptan Hydrobromide,CN1CCCC1CC1=CNC2=C1C=C(CCS(=O)(=O)C1=CC=CC=C1)C=C2,Hepatic necrosis,Mouse,-2.6020599913279625,Repeated,Oral,"FDA approval package document: Pharmacology Review 021016/S-000 Part 01, page:42 PDF 1977k",https://www.pharmapendium.com/browse/fda/Eletriptan Hydrobromide/f735f6506578d3a0425a66934cbf0624?reference=42,2002.0
51,97,246,Eltrombopag Olamine,CC1=CC=C(N2NC(C)=C(N=NC3=C(O)C(C4=CC=CC(C(=O)O)=C4)=CC=C3)C2=O)C=C1C,Hepatic necrosis,Mouse,-2.3010299956639813,Repeated,Oral,"FDA approval package document: Pharmacology Review 022291/S-000 Part 01, page:82 PDF 6006k",https://www.pharmapendium.com/browse/fda/Eltrombopag Olamine/a6b4e32902d1172955bc3153b3e0fa33?reference=82,2008.0
52,98,248,Eluxadoline,COC1=C(C(=O)O)C=C(CN(C(=O)C(N)CC2=C(C)C=C(C(N)=O)C=C2C)C(C)C2=NC(C3=CC=CC=C3)=CN2)C=C1,Hepatic necrosis,Rat,-2.6989700043360187,Repeated,Oral,"FDA approval package document: Pharmacology Review 206940/S-000 Part 03, page:87 PDF 24615k",https://www.pharmapendium.com/browse/fda/Eluxadoline/bf87aa3e04f882173ab67b80daf2c3dc?reference=87,2014.0
53,101,254,Erlotinib Hydrochloride,C#CC1=CC(NC2=NC=NC3=CC(OCCOC)=C(OCCOC)C=C23)=CC=C1,Hepatic necrosis,Rat,-0.7634279935629372,Repeated,Oral,"FDA approval package document: Pharmacology Review 021743/S-000, page:67 PDF 2897k",https://www.pharmapendium.com/browse/fda/Erlotinib Hydrochloride/54ec5af6b2ede34590fb1e26ebb7ba4d?reference=67,2004.0
54,102,259,Eslicarbazepine Acetate,CC(=O)OC1CC2=C(C=CC=C2)N(C(N)=O)C2=C1C=CC=C2,Hepatic necrosis,Mouse,-2.397940008672037,Repeated,Oral,"FDA approval package document: Pharmacology Review 022416/S-000 Part 12, page:19 PDF 5225k",https://www.pharmapendium.com/browse/fda/Eslicarbazepine Acetate/69def65e90334065195d6525ec9135c2?reference=19,2009.0
55,103,262,Esomeprazole Sodium,COC1=CC2=C(C=C1)NC([S+]([O-])CC1=NC=C(C)C(OC)=C1C)=N2,Hepatic necrosis,Rat,-1.9030899869919435,Repeated,Intravenous,"FDA approval package document: Pharmacology Review 021689/S-000, page:37 PDF 7706k",https://www.pharmapendium.com/browse/fda/Esomeprazole Sodium/7810e15b399f55edb2f5aa587ceae5d0?reference=37,2004.0
56,105,268,Feprazone,CC(C)=CCC1=C(O)N(C2=CC=CC=C2)N(C2=CC=CC=C2)C1=O,Hepatic necrosis,Rat,-2.7781512503836434,Repeated,Oral,"Reference from PharmaPendium Published Toxicity: Toxicology and Applied Pharmacology 64,255,1982   ---   DOI:10.1016/0041-008X(82)90222-8   ISSN:0041-008X   JOURNAL:Toxicology and Applied Pharmacology   PAGES:255   VOLUME:64",http://dx.doi.org/10.1016/0041-008X(82)90222-8,1982.0
57,110,277,Fondaparinux Sodium,COC1OC(COS(=O)(=O)O)C(OC2OC(C(=O)O)C(OC3OC(COS(=O)(=O)O)C(OC4OC(C(=O)O)C(OC5OC(COS(=O)(=O)O)C(O)C(O)C5NS(=O)(=O)O)C(O)C4O)C(OS(=O)(=O)O)C3NS(=O)(=O)O)C(O)C2OS(=O)(=O)O)C(O)C1NS(=O)(=O)O,Hepatic necrosis,Rat,-1.0,Repeated,Intravenous,"FDA approval package document: Pharmacology Review 021345/S-000 Part 02, page:22 PDF 1712k",https://www.pharmapendium.com/browse/fda/Fondaparinux Sodium/944979fb1554aed80fc853a4961e67c8?reference=22,2001.0
58,111,278,Fosamprenavir Calcium,CC(C)CN(CC(O[PH](=O)(=O)O)C(CC1=CC=CC=C1)NC(=O)OC1CCOC1)S(=O)(=O)C1=CC=C(N)C=C1,Hepatic necrosis,Rat,-3.3502480183341627,Repeated,Oral,"FDA approval package document: Pharmacology Review 021548/S-000 Part 03, page:30 PDF 1596k",https://www.pharmapendium.com/browse/fda/Fosamprenavir Calcium/742de3ff271fc37c80260f31a62784fa?reference=30,2003.0
59,112,280,Fospropofol Disodium,CC(C)C1=CC=CC(C(C)C)=C1OCO[PH](=O)(=O)O,Hepatic necrosis,Rat,-1.9890046156985368,Repeated,Intravenous,"FDA approval package document: Pharmacology Review 022244/S-000 Part 02, page:9 PDF 6204k",https://www.pharmapendium.com/browse/fda/Fospropofol Disodium/1c5008b99bf2f4864d62595ac44f14af?reference=9,2008.0
60,113,282,Gabapentin,NCC1(CC(=O)O)CCCCC1,Hepatic necrosis,Rat,-3.00966331667938,Repeated,Intraperitoneal,Reference from PharmaPendium Published Toxicity: 373075182   ---   ISSN:1735-9694   JOURNAL:Acta Medica Iranica   PAGES:830   VOLUME:51,,2013.0
61,116,292,Gemfibrozil,CC1=CC(OCCCC(C)(C)C(=O)O)=C(C)C=C1,Hepatic necrosis,Rat,-1.3010299956639813,Repeated,Oral,Reference from PharmaPendium Published Toxicity: 361522984   ---   DOI:10.1016/S1734-1140(11)70410-8   ISSN:1734-1140   JOURNAL:Pharmacological Reports   PAGES:157   VOLUME:63,http://dx.doi.org/10.1016/S1734-1140(11)70410-8,2011.0
62,117,293,Glucagon,CSCCC(NC(=O)C(CC(C)C)NC(=O)C(CC1=CC=C(O)C=C1)NC(=O)C(CCC(N)=O)NC(=O)C(NC(=O)C(CC1=CC=CC=C1)NC(=O)C(CC(=O)O)NC(=O)C(CCC(N)=O)NC(=O)C(C)NC(=O)C(CCCN=C(N)N)NC(=O)C(CCCN=C(N)N)NC(=O)C(CO)NC(=O)C(CC(=O)O)NC(=O)C(CC(C)C)NC(=O)C(CC1=CC=C(O)C=C1)NC(=O)C(CCCCN)NC(=O)C(CO)NC(=O)C(CC1=CC=C(O)C=C1)NC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C(NC(=O)C(CC1=CC=CC=C1)NC(=O)C(NC(=O)CNC(=O)C(CCC(N)=O)NC(=O)C(CO)NC(=O)C(N)CC1=CNC=N1)C(C)O)C(C)O)C(C)C)C(=O)NC(CC(N)=O)C(=O)NC(C(=O)O)C(C)O,Hepatic necrosis,Rat,-0.3010299956639812,Repeated,Subcutaneous,"FDA approval package document: Pharmacology Review 212097/S-000, page:21 PDF 6872k",https://www.pharmapendium.com/browse/fda/Glucagon/0403576e5fc149072fce40908306c885?reference=21,2013.0
63,119,295,Glycopyrrolate,C[N+]1(C)CCC(OC(=O)C(O)(C2=CC=CC=C2)C2CCCC2)C1,Hepatic necrosis,Mouse,-0.9030899869919436,Repeated,Oral,"FDA approval package document: Pharmacology Review 207923/S-000 Part 08, page:18 PDF 2638k",https://www.pharmapendium.com/browse/fda/Glycopyrrolate/d8422c425a09593c4eda3315d45259ff?reference=18,2015.0
64,120,300,Granisetron,CN1C2CCCC1CC(NC(=O)C1=NN(C)C3=C1C=CC=C3)C2,Hepatic necrosis,Rat,-2.096910013008056,Repeated,Oral,"FDA approval package document: Pharmacology Review 022198/S-000, page:50 PDF 4033k",https://www.pharmapendium.com/browse/fda/Granisetron/aeb89a6899d842b3f0fa9b7a0295df59?reference=50,2007.0
65,121,301,Hydrocortisone,CC12CCC(=O)C=C1CCC1C2C(O)CC2(C)C1CCC2(O)C(=O)CO,Hepatic necrosis,Rabbit,-1.1760912590556811,Repeated,Intramuscular,"EMA approval document: Assessment Report EMA/CHMP/424438/2011; EMEA/H/C/2185, page:17 PDF 888k",https://www.pharmapendium.com/browse/ema/Hydrocortisone/4e60a37ae57756d34dd06c403ec4c55e?reference=17,2011.0
66,122,302,Ibandronate Sodium,CCCCCN(C)CCC(O)([PH](=O)(=O)O)[PH](=O)(=O)O,Hepatic necrosis,Rat,-1.9294189257142929,Repeated,Oral,"FDA approval package document: Pharmacology Review 021455/S-000 Part 02, page:40 PDF 1440k",https://www.pharmapendium.com/browse/fda/Ibandronate Sodium/bc5863319b5349c27662cae1be705811?reference=40,2003.0
67,123,303,Ibrutinib,C=CC(=O)N1CCCC(N2N=C(C3=CC=C(OC4=CC=CC=C4)C=C3)C3=C(N)N=CN=C32)C1,Hepatic necrosis,Rat,-2.3521825181113627,Repeated,Oral,"FDA approval package document: Pharmacology Review 205552/S-000 Part 02, page:40 PDF 14456k",https://www.pharmapendium.com/browse/fda/Ibrutinib/f65b839909bc2f37b055dfeecf594d0f?reference=40,2013.0
68,124,305,Ibuprofen,CC(C)CC1=CC=C(C(C)C(=O)O)C=C1,Hepatic necrosis,Mouse,-2.4771212547196626,Repeated,Oral,"FDA approval package document: Approval Package 017463/S-034, S-063, S-049, S-052, S-097, S-098, S-095; 019012/S-013 Part 01, page:9 PDF 4908k",https://www.pharmapendium.com/browse/fda/Ibuprofen/d16be14be7684a5a7e82ebbf532ebe1d?reference=9,1982.0
69,126,307,Indinavir Sulfate,CC(C)(C)NC(=O)C1CN(CC2=CC=CN=C2)CCN1CC(O)CC(CC1=CC=CC=C1)C(=O)NC1C2=CC=CC=C2CC1O,Hepatic necrosis,Rat,-3.24551266781415,Repeated,Oral,"FDA approval package document: Pharmacology Review 020685, page:56 PDF 2098k",https://www.pharmapendium.com/browse/fda/Indinavir Sulfate/d214ba9ff666ee648ab3c78ad1eff978?reference=56,1996.0
70,128,312,Ipratropium Bromide,CC(C)[N+]1(C)C2CCC1CC(OC(=O)C(CO)C1=CC=CC=C1)C2,Hepatic necrosis,Rat,-8.957128197676813,Repeated,Inhalation,"FDA approval package document: Pharmacology Review 020393, page:7 PDF 708k",https://www.pharmapendium.com/browse/fda/Ipratropium Bromide/6a16c834673c1c5c0d53753cece6598b?reference=7,1994.0
71,129,314,Irbesartan,CCCCC1=NC2(CCCC2)C(=O)N1CC1=CC=C(C2=CC=CC=C2C2=NNN=N2)C=C1,Hepatic necrosis,Mouse,-3.255272505103306,Repeated,Oral,"FDA approval package document: Pharmacology Review 020757/S-000 Part 02, page:63 PDF 3036k",https://www.pharmapendium.com/browse/fda/Irbesartan/4db01d512b5ac047c9bdf97b6883d20c?reference=63,1997.0
72,130,320,Irinotecan Hydrochloride,CCC1=C2CN3C(=CC4=C(COC(=O)C4(O)CC)C3=O)C2=NC2=CC=C(OC(=O)N3CCC(N4CCCCC4)CC3)C=C12,Hepatic necrosis,Rat,-1.7481880270062005,Repeated,Intravenous,"FDA approval package document: Medical/Clinical Review 207793/S-000 Part 02, page:4 PDF 2613k",https://www.pharmapendium.com/browse/fda/Irinotecan Hydrochloride/1e151343d53bcf580d5b5ace31a64c8f?reference=4,2015.0
73,131,322,Isoniazid,NNC(=O)C1=CC=NC=C1,Hepatic necrosis,Rat,-0.8750612633917001,Repeated,Oral,"Reference from PharmaPendium Published Toxicity: Toxicology and Applied Pharmacology 8,325,1966   ---   DOI:10.1016/S0041-008X(66)80019-4   ISSN:0041-008X   JOURNAL:Toxicology and Applied Pharmacology   PAGES:325   VOLUME:8",http://dx.doi.org/10.1016/S0041-008X(66)80019-4,1966.0
74,132,324,Istradefylline,CCN1C(=O)C2=C(N=C(/C=C/C3=CC=C(OC)C(OC)=C3)N2C)N(CC)C1=O,Hepatic necrosis,Mouse,-2.6989700043360187,Repeated,Oral,"FDA approval package document: Pharmacology Review 022075/S-000 Part 08, page:8 PDF 347k",https://www.pharmapendium.com/browse/fda/Istradefylline/106ca5bf7016d57b02089845d8572a27?reference=8,2008.0
75,134,327,Ivacaftor,CC(C)(C)C1=C(O)C=C(NC(=O)C2=CNC3=CC=CC=C3C2=O)C(C(C)(C)C)=C1,Hepatic necrosis,Rat,-2.397940008672037,Repeated,Oral,"FDA approval package document: Pharmacology Review 203188/S-000 Part 01, page:2 PDF 381k",https://www.pharmapendium.com/browse/fda/Ivacaftor/28c7306a2e8eb67b5eb2ec904966bf5a?reference=2,2012.0
76,136,338,Ixabepilone,C/C(=C\C1=CSC(C)=N1)C1CC2OC2(C)CCCC(C)C(O)C(C)C(=O)C(C)(C)C(O)CC(=O)N1,Hepatic necrosis,Rat,-0.4771212547196624,Repeated,Unreported,"EMA approval document: Withdrawal Public Statement EMEA/594033/2008, page:11 PDF 915k",https://www.pharmapendium.com/browse/ema/Ixabepilone/54dfe64ad0157f77f787a5fe8c8d269b?reference=11,2009.0
77,138,342,Ketotifen Fumarate,CN1CCC(=C2C3=CC=CC=C3CC(=O)C3=C2C=CS3)CC1,Hepatic necrosis,Rat,-2.161368002234975,Repeated,Oral,"FDA approval package document: Pharmacology Review 021066/S-000 Part 02, page:42 PDF 1839k",https://www.pharmapendium.com/browse/fda/Ketotifen Fumarate/957be5c997240e08e60d15180080f1d2?reference=42,1999.0
78,144,357,Letrozole,N#CC1=CC=C(C(C2=CC=C(C#N)C=C2)N2C=NC=N2)C=C1,Hepatic necrosis,Rat,-0.0,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 020726 Part 01, page:24 PDF 3469k",https://www.pharmapendium.com/browse/fda/Letrozole/72bacd76e87e03b74f76cae96cafa6eb?reference=24,1996.0
79,145,358,Levodopa,NC(CC1=CC(O)=C(O)C=C1)C(=O)O,Hepatic necrosis,Rat,-2.255272505103306,Repeated,Inhalation,"FDA approval package document: Pharmacology Review 209184/S-000, page:25 PDF 4049k",https://www.pharmapendium.com/browse/fda/Levodopa/d96ccac2ca030525b6d86f10afa2d7fe?reference=25,2018.0
80,146,359,Levothyroxine Sodium,NC(CC1=CC(I)=C(OC2=CC(I)=C(O)C(I)=C2)C(I)=C1)C(=O)O,Hepatic necrosis,Rat,-8.204119982655925,Repeated,Oral,"FDA approval package document: Pharmacology Review 021402/S-000, page:13 PDF 1000k",https://www.pharmapendium.com/browse/fda/Levothyroxine Sodium/b6972da71e31a03a23f215041e022576?reference=13,2001.0
81,147,361,Linaclotide,CC1NC(=O)C2CCCN2C(=O)C(CC(N)=O)NC(=O)C2CSSCC(N)C(=O)NC3CSSCC(NC1=O)C(=O)NC(C(C)O)C(=O)NCC(=O)NC(C(=O)NC(CC1=CC=C(O)C=C1)C(=O)O)CSSCC(NC(=O)C(CC1=CC=C(O)C=C1)NC(=O)C(CCC(=O)O)NC3=O)C(=O)N2,Hepatic necrosis,Rat,-2.0,Repeated,Oral,"FDA approval package document: Pharmacology Review 202811/S-000 Part 08, page:23 PDF 4207k",https://www.pharmapendium.com/browse/fda/Linaclotide/343681840937dbd8c414ed9a7bf23fcf?reference=23,2012.0
82,148,362,Lisdexamfetamine Dimesylate,CC(CC1=CC=CC=C1)NC(=O)C(N)CCCCN,Hepatic necrosis,Rat,-1.6020599913279625,Repeated,Oral,"FDA approval package document: Pharmacology Review 021977/S-000, page:155 PDF 20084k",https://www.pharmapendium.com/browse/fda/Lisdexamfetamine Dimesylate/346930b3697114b80f4b40b7749ab7f7?reference=155,2007.0
83,152,369,Lurbinectedin,COC1=CC2=C(C=C1)NC1=C2CCNC12CSC1C3=C(OC(C)=O)C(C)=C4OCOC4=C3C(COC2=O)N2C(O)C3CC4=C(C(O)=C(OC)C(C)=C4)C(C12)N3C,Hepatic necrosis,Rat,-0.9542425094393248,Repeated,Intravenous,"FDA approval package document: Approval Package 213702/S-000 Part 02, page:14 PDF 1454k",https://www.pharmapendium.com/browse/fda/Lurbinectedin/b7f6318682b57e077be90d31a6c3959b?reference=14,2020.0
84,154,373,Malathion,CCOC(=O)CC(SP(=S)(OC)OC)C(=O)OCC,Hepatic necrosis,Mouse,-1.1760912590556811,Repeated,Oral,Reference from PharmaPendium Published Toxicity: 602567443   ---   DOI:10.13040/IJPSR.0975-8232.6(3).1043-48   ISSN:2320-5148   JOURNAL:International Journal of Pharmaceutical Sciences and Research   PAGES:1043   VOLUME:6,http://dx.doi.org/10.13040/IJPSR.0975-8232.6(3).1043-48,2015.0
85,156,383,Meloxicam,CC1=CN=C(NC(=O)C2C(=O)C3=CC=CC=C3S(=O)(=O)N2C)S1,Hepatic necrosis,Rat,-1.0413926851582251,Repeated,Intramuscular,Reference from PharmaPendium Published Toxicity: E-52869227   ---   DOI:10.1016/j.injury.2013.10.002   ISSN:0020-1383   JOURNAL:Injury   PAGES:185   VOLUME:45,http://dx.doi.org/10.1016/j.injury.2013.10.002,2014.0
86,157,387,Memantine Hydrochloride,CC12CC3CC(C)(C1)CC(N)(C3)C2,Hepatic necrosis,Mouse,-1.9030899869919435,Repeated,Oral,"FDA approval package document: Pharmacology Review 021487/S-000 Part 03, page:29 PDF 1499k",https://www.pharmapendium.com/browse/fda/Memantine Hydrochloride/cb3465df10a628433d56977717a4890a?reference=29,2003.0
87,158,388,Methapyrilene Hydrochloride,CN(C)CCN(CC1=CC=CS1)C1=NC=CC=C1,Hepatic necrosis,Rat,-1.1760912590556811,Repeated,Oral,"Reference from PharmaPendium Published Toxicity: Toxicology 250,15,2008   ---   DOI:10.1016/j.tox.2008.05.013   ISSN:0300-483X   JOURNAL:Toxicology   PAGES:15   VOLUME:250",http://dx.doi.org/10.1016/j.tox.2008.05.013,2008.0
88,159,389,Methotrexate Sodium,CN(CC1=NC2=C(N)N=C(N)N=C2N=C1)C1=CC=C(C(=O)NC(CCC(=O)O)C(=O)O)C=C1,Hepatic necrosis,Mouse,-1.0,Repeated,Oral,Reference from PharmaPendium Published Toxicity: 620740248   ---   DOI:10.1007/s12247-018-9314-4   ISSN:1872-5120   JOURNAL:Journal of Pharmaceutical Innovation   PAGES:213   VOLUME:13,http://dx.doi.org/10.1007/s12247-018-9314-4,2018.0
89,160,391,Methoxsalen,COC1=C2OC(=O)C=CC2=CC2=C1OC=C2,Hepatic necrosis,Rat,-1.1139433523068367,Repeated,Oral,"Reference from PharmaPendium Published Toxicity: Toxicology 56,123,1989   ---   DOI:10.1016/0300-483X(89)90127-3   ISSN:0300-483X   JOURNAL:Toxicology   PAGES:123   VOLUME:56",http://dx.doi.org/10.1016/0300-483X(89)90127-3,1989.0
90,161,392,Methyl Tert-Butyl Ether,COC(C)(C)C,Hepatic necrosis,Mouse,-2.6989700043360187,Repeated,Intraperitoneal,Reference from PharmaPendium Published Toxicity: 2004110882   ---   DOI:10.22034/IJPS.2018.88396.1446   ISSN:1735-2444   JOURNAL:Iranian Journal of Pharmaceutical Sciences   PAGES:17   VOLUME:15,http://dx.doi.org/10.22034/IJPS.2018.88396.1446,2020.0
91,162,393,Methylnaltrexone Bromide,C[N+]1(CC2CC2)CCC23C4=C5OC2C(=O)CCC3(O)C1CC4=CC=C5O,Hepatic necrosis,Mouse,-3.1760912590556813,Repeated,Oral,"FDA approval package document: Pharmacology Review 021964/S-000 Part 02, page:11 PDF 5240k",https://www.pharmapendium.com/browse/fda/Methylnaltrexone Bromide/27c637bf2c53b65948b61cd3cf377771?reference=11,2008.0
92,163,395,Midostaurin,COC1C(N(C)C(=O)C2=CC=CC=C2)CC2OC1(C)N1C3=C(C=CC=C3)C3=C4CNC(=O)C4=C4C5=C(C=CC=C5)N2C4=C31,Hepatic necrosis,Rat,-2.3010299956639813,Repeated,Oral,"EMA approval document: Assessment Report EMA/CHMP/516229/2017; EMEA/H/C/004095/0000, page:37 PDF 7394k",https://www.pharmapendium.com/browse/ema/Midostaurin/7ca7a1ea535abba143f839369c00f2d4?reference=37,2017.0
93,164,397,Mifepristone,CC#CC1(O)CCC2C3=C(C4=C(CC3)CC(=O)CC4)C(C3=CC=C(N(C)C)C=C3)CC21C,Hepatic necrosis,Rat,-2.096910013008056,Repeated,Oral,"FDA approval package document: Pharmacology Review 202107/S-000 Part 04, page:29 PDF 7149k",https://www.pharmapendium.com/browse/fda/Mifepristone/3462b48517ccc84185c9dd06f991e8f1?reference=29,2012.0
94,165,398,Miglustat,CCCCN1CC(O)C(O)C(O)C1CO,Hepatic necrosis,Rat,-2.9586741242384,Repeated,Oral,"FDA approval package document: Pharmacology Review 021348/S-000 Part 03, page:29 PDF 1693k",https://www.pharmapendium.com/browse/fda/Miglustat/b01e5a418b4eca4dbd4aa155673bf690?reference=29,2003.0
95,166,411,Milrinone Lactate,CC1=C(C2=CC=NC=C2)C=C(C#N)C(=O)N1,Hepatic necrosis,Rat,-1.3979400086720375,Repeated,Oral,"FDA approval package document: Approval Package 019436/S-003, S-008 Part 08, page:47 PDF 4981k",https://www.pharmapendium.com/browse/fda/Milrinone Lactate/1f464b9e59f31b3cb8c728ff4e84559d?reference=47,1992.0
96,167,412,Mirabegron,NC1=NC(CC(=O)NC2=CC=C(CCNCC(O)C3=CC=CC=C3)C=C2)=CS1,Hepatic necrosis,Rat,-2.3010299956639813,Repeated,Oral,"FDA approval package document: Pharmacology Review 202611/S-000 Part 04, page:56 PDF 13497k",https://www.pharmapendium.com/browse/fda/Mirabegron/f6fa9f6e34b29146f414d544cc752465?reference=56,2012.0
97,168,414,Mitoxantrone Hydrochloride,OCCN=CCNC1=CC=C(NCCNCCO)C2=C1C(O)=C1C(O)=CC=C(O)C1=C2O,Hepatic necrosis,Rat,-1.3010299956639813,Repeated,Intraperitoneal,Reference from PharmaPendium Published Toxicity: 52845285   ---   DOI:10.1111/bcpt.12143   ISSN:1742-7835   JOURNAL:Basic and Clinical Pharmacology and Toxicology   PAGES:9   VOLUME:114,http://dx.doi.org/10.1111/bcpt.12143,2014.0
98,169,415,Moexipril Hydrochloride,CCOC(=O)C(CCC1=CC=CC=C1)NC(C)C(=O)N1CC2=CC(OC)=C(OC)C=C2CC1C(=O)O,Hepatic necrosis,Mouse,-1.8750612633917,Repeated,Oral,"FDA approval package document: Pharmacology Review 020312 Part 03, page:11 PDF 904k",https://www.pharmapendium.com/browse/fda/Moexipril Hydrochloride/d279850af0b5ccacb95e276d64dd813b?reference=11,1993.0
99,171,418,Monosodium L-Glutamate,NC(CCC(=O)O)C(=O)O,Hepatic necrosis,Mouse,-0.0,Repeated,Oral,Reference from PharmaPendium Published Toxicity: 2002200452   ---   DOI:10.3923/ijp.2019.449.456   ISSN:1811-7775   JOURNAL:International Journal of Pharmacology   PAGES:449   VOLUME:15,http://dx.doi.org/10.3923/ijp.2019.449.456,2019.0
100,173,420,Naloxegol Oxalate,C=CCN1CCC23C4=C5C=CC(O)=C4OC2C(OCCOCCOCCOCCOCCOCCOCCOC)CCC3(O)C1C5,Hepatic necrosis,Mouse,-2.7617608341954742,Repeated,Oral,"FDA approval package document: Pharmacology Review 204760/S-000, page:290 PDF 33475k",https://www.pharmapendium.com/browse/fda/Naloxegol Oxalate/170cfe085c4dee733a6c9749a490c3d8?reference=290,2009.0
101,174,429,Naratriptan Hydrochloride,CNS(=O)(=O)CCC1=CC=C2NC=C(C3CCN(C)CC3)C2=C1,Hepatic necrosis,Rat,-2.531478917042255,Repeated,Oral,"FDA approval package document: Pharmacology Review 020763/S-000, page:27 PDF 1298k",https://www.pharmapendium.com/browse/fda/Naratriptan Hydrochloride/eee5ffe18b64356e5484cc4b58906112?reference=27,1997.0
102,175,431,Nevirapine,CC1=CC=NC2=C1NC(=O)C1=C(N=CC=C1)N2C1CC1,Hepatic necrosis,Rat,-2.401400540781544,Repeated,Intragastric,Reference from PharmaPendium Published Toxicity: 365295535   ---   DOI:10.1177/0960327111424304   ISSN:0960-3271   JOURNAL:Human and Experimental Toxicology   PAGES:676   VOLUME:31,http://dx.doi.org/10.1177/0960327111424304,2012.0
103,176,433,Nicotine,CN1CCCC1C1=CC=CN=C1,Hepatic necrosis,Rat,-1.8084360542881115,Repeated,Intraperitoneal,Reference from PharmaPendium Published Toxicity: 605131271   ---   DOI:10.1093/alcalc/agu083   ISSN:0735-0414   JOURNAL:Alcohol and Alcoholism   PAGES:118   VOLUME:50,http://dx.doi.org/10.1093/alcalc/agu083,2015.0
104,177,436,Obeticholic Acid,CCC1C(O)C2C3CCC(C(C)CCC(=O)O)C3(C)CCC2C2(C)CCC(O)CC12,Hepatic necrosis,Mouse,-1.6232492903979006,Repeated,Oral,"FDA approval package document: Pharmacology Review 207999/S-000 Part 03, page:27 PDF 13571k",https://www.pharmapendium.com/browse/fda/Obeticholic Acid/a2a2a577ec5b639dc211430b2c08567e?reference=27,2016.0
105,178,438,Olopatadine Hydrochloride,CN(C)CC/C=C1/C2=CC=CC=C2COC2=CC=C(CC(=O)O)C=C12,Hepatic necrosis,Rat,-2.7781512503836434,Repeated,Oral,"FDA approval package document: Pharmacology Review 021861/S-000 Part 03, page:19 PDF 7519k",https://www.pharmapendium.com/browse/fda/Olopatadine Hydrochloride/e5ba2ffbfb9892a3248b3e0faec4578c?reference=19,2008.0
106,179,439,Omacetaxine Mepesuccinate,COC(=O)CC(O)(CCCC(C)(C)O)C(=O)OC1C(OC)=CC23CCCN2CCC2=CC4=C(C=C2C13)OCO4,Hepatic necrosis,Mouse,-2.2174839442139063,Repeated,Subcutaneous,"FDA approval package document: Pharmacology Review 203585/S-000 Part 05, page:38 PDF 8962k",https://www.pharmapendium.com/browse/fda/Omacetaxine Mepesuccinate/a070c7ba71630a14ca9434d613ccefa8?reference=38,2012.0
107,180,440,Omeprazole,COC1=CC=C2NC([S+]([O-])CC3=NC=C(C)C(OC)=C3C)=NC2=C1,Hepatic necrosis,Rat,-0.0,Repeated,Oral,"FDA approval package document: Approval Package 019810/S-002, S-007, S-036, S-037, S-009, S-010, S-022, S-035, S-019, S-023, S-025, S-033, S-034; 050662/S-010 Part 05, page:32 PDF 5403k",https://www.pharmapendium.com/browse/fda/Omeprazole/c565d4e7138a0a91b62387b792832164?reference=32,1990.0
108,182,442,Orlistat,CCCCCCCCCCCC(CC1OC(=O)C1CCCCCC)OC(=O)C(CC(C)C)NC=O,Hepatic necrosis,Rat,-2.0,Repeated,Intravenous,"FDA approval package document: Pharmacology Review 020766/S-000 Part 05, page:10 PDF 780k",https://www.pharmapendium.com/browse/fda/Orlistat/72e8a579f230ef5ddff24ca06a7344e5?reference=10,1999.0
109,183,445,Oxcarbazepine,NC(=O)N1C2=CC=CC=C2CC(=O)C2=CC=CC=C21,Hepatic necrosis,Rat,-2.798190099822149,Repeated,Oral,"FDA approval package document: Pharmacology Review 021014/S-000 Part 01, page:25 PDF 1731k",https://www.pharmapendium.com/browse/fda/Oxcarbazepine/99f13ced7ea7ed3f7f343c0b64456e7a?reference=25,1999.0
110,184,451,Ozanimod Hydrochloride,CC(C)OC1=C(C#N)C=C(C2=NC(C3=C4CCC(NCCO)C4=CC=C3)=NO2)C=C1,Hepatic necrosis,Mouse,-1.3979400086720375,Repeated,Oral,"FDA approval package document: Pharmacology Review 209899/S-000, page:69 PDF 19004k",https://www.pharmapendium.com/browse/fda/Ozanimod Hydrochloride/a736fe86a523a011de6082eb570d5ce6?reference=69,2020.0
111,185,452,Paclitaxel,CC(=O)OC1=C2C(C)C(OC(=O)C(O)C(NC(=O)C3=CC=CC=C3)C3=CC=CC=C3)CC(O)(C(OC(=O)C3=CC=CC=C3)C3C4(OC(C)=O)COC4CC(O)C3(C)C1=O)C2(C)C,Hepatic necrosis,Rat,-0.6989700043360189,Repeated,Intraperitoneal,"FDA approval package document: Approval Package 020262 Part 03, page:26 PDF 5477k",https://www.pharmapendium.com/browse/fda/Paclitaxel/ff3e75f75d8129aa72b46b11da8f1a26?reference=26,1992.0
112,186,454,Palonosetron Hydrochloride,O=C1C2=CC=CC3=C2C(CCC3)CN1C1CN2CCC1CC2,Hepatic necrosis,Rat,-2.255272505103306,Repeated,Oral,"FDA approval package document: Pharmacology Review 022233/S-000, page:14 PDF 1314k",https://www.pharmapendium.com/browse/fda/Palonosetron Hydrochloride/f8001dc8d7fdce366d1d95ec632d78ae?reference=14,2010.0
113,187,457,Panobinostat Lactate,CC1=C(CCNCC2=CC=C(/C=C/C(O)=NO)C=C2)C2=CC=CC=C2N1,Hepatic necrosis,Rat,-2.0,Repeated,Oral,"EMA approval document: Other Information from EMA EMA/COMP/470322/2015, page:36 PDF 6774k",https://www.pharmapendium.com/browse/ema/Panobinostat Lactate/9a5774092cbb1293b1d7fa2ae0fd7403?reference=36,2015.0
114,193,481,Phenobarbital,CCC1(C2=CC=CC=C2)C(=O)NC(=O)NC1=O,Hepatic necrosis,Mouse,-0.6989700043360189,Repeated,Oral,Reference from PharmaPendium Published Toxicity: 607644124   ---   DOI:10.1016/j.etp.2015.12.005   ISSN:0940-2993   JOURNAL:Experimental and Toxicologic Pathology   PAGES:233   VOLUME:68,http://dx.doi.org/10.1016/j.etp.2015.12.005,2016.0
115,195,483,Piperacillin Sodium,CCN1CCN(C(=O)NC(C(=O)NC2C(=O)N3C2SC(C)(C)C3C(=O)O)C2=CC=CC=C2)C(=O)C1=O,Hepatic necrosis,Rat,-3.6020599913279625,Repeated,Intraperitoneal,"FDA approval package document: Approval Package 050545 Part 03, page:49 PDF 5811k",https://www.pharmapendium.com/browse/fda/Piperacillin Sodium/8e9d225de2a4b238e30fda2f67354300?reference=49,1981.0
116,196,484,Pirfenidone,CC1=CN(C2=CC=CC=C2)C(=O)C=C1,Hepatic necrosis,Rat,-3.0,Repeated,Oral,"FDA approval package document: Pharmacology Review 208780/S-000, page:14 PDF 2378k",https://www.pharmapendium.com/browse/fda/Pirfenidone/f902707a86da2412b7717fdac72f077c?reference=14,2016.0
117,200,495,Pravastatin Sodium,CCC(C)C(=O)OC1CC(O)C=C2C=CC(C)C(CCC(O)CC(O)CC(=O)O)C21,Hepatic necrosis,Rat,-1.7609248484091329,Repeated,Oral,"FDA approval package document: Approval Package 019898/S-003, S-004, S-005, S-006, S-007, S-008, S-009, S-010, S-011, S-013, S-015, S-017, S-020 Part 04, page:4 PDF 1182k",https://www.pharmapendium.com/browse/fda/Pravastatin Sodium/ccd6f2607f9ec13cfe9dceac3d2b0dec?reference=4,1991.0
118,201,501,Prednisolone,CC12C=CC(=O)C=C1CCC1C2C(O)CC2(C)C1CCC2(O)C(=O)CO,Hepatic necrosis,Mouse,-1.146128035678238,Repeated,Unreported,Reference from PharmaPendium Published Toxicity: 607039269   ---   DOI:10.1097/MPH.0000000000000484   ISSN:1077-4114   JOURNAL:Journal of Pediatric Hematology/Oncology   PAGES:e42   VOLUME:38,http://dx.doi.org/10.1097/MPH.0000000000000484,2016.0
119,202,502,Propranolol Hydrochloride,CC(C)NCC(O)COC1=C2C=CC=CC2=CC=C1,Hepatic necrosis,Mouse,-0.6020599913279624,Repeated,Intraperitoneal,Reference from PharmaPendium Published Toxicity: E-52700989   ---   DOI:10.1016/j.bbrc.2013.07.005   ISSN:0006-291X   JOURNAL:Biochemical and Biophysical Research Communications   PAGES:597   VOLUME:437,http://dx.doi.org/10.1016/j.bbrc.2013.07.005,2013.0
120,203,503,Pyrazinamide,NC(=O)C1=NC=CN=C1,Hepatic necrosis,Rat,-4.447158031342219,Repeated,Intragastric,Reference from PharmaPendium Published Toxicity: 51921340   ---   DOI:10.1002/jat.2736   ISSN:0260-437X   JOURNAL:Journal of applied toxicology   PAGES:807   VOLUME:33,http://dx.doi.org/10.1002/jat.2736,2013.0
121,204,505,Quizartinib Dihydrochloride,CC(C)(C)C1=CC(NC(=O)NC2=CC=C(C3=CN4C(=N3)SC3=CC(OCCN5CCOCC5)=CC=C34)C=C2)=NO1,Hepatic necrosis,Rat,-1.4771212547196624,Repeated,Oral,"EMA approval document: Public Assessment Report EMA/CHMP/602286/2019; EMEA/H/C/004468/0000, page:28 PDF 5534k",https://www.pharmapendium.com/browse/ema/Quizartinib Dihydrochloride/e5a1774afc92002d3e3710192a619e0e?reference=28,2019.0
122,205,506,Rabeprazole Sodium,COCCCOC1=C(C)C(C[S+]([O-])C2=NC3=C(C=CC=C3)N2)=NC=C1,Hepatic necrosis,Mouse,-2.3010299956639813,Repeated,Oral,"FDA approval package document: Pharmacology Review 020973 Part 02, page:4 PDF 2627k",https://www.pharmapendium.com/browse/fda/Rabeprazole Sodium/2e2190991b88b68443eef79d86332942?reference=4,1998.0
123,206,511,Ramelteon,CCC(=O)NCCC1CCC2=CC=C3OCCC3=C21,Hepatic necrosis,Mouse,-2.9242792860618816,Repeated,Oral,"FDA approval package document: Pharmacology Review 021782/S-000, page:198 PDF 22920k",https://www.pharmapendium.com/browse/fda/Ramelteon/e747eec7ca64f09ae8c52babd18274c4?reference=198,2004.0
124,207,516,Rasagiline Mesylate,C#CCNC1CCC2=CC=CC=C21,Hepatic necrosis,Mouse,-1.1760912590556811,Repeated,Oral,"FDA approval package document: Pharmacology Review 021641/S-000 Part 02, page:86 PDF 3944k",https://www.pharmapendium.com/browse/fda/Rasagiline Mesylate/023eb7e29544e727a5e4fed62d4747ff?reference=86,2006.0
125,208,517,Ribavirin,NC(=O)C1=NN(C2OC(CO)C(O)C2O)C=N1,Hepatic necrosis,Rat,-2.0589778599593376,Repeated,Oral,"FDA approval package document: Pharmacology Review 020903/S-000 Part 01, page:29 PDF 1508k",https://www.pharmapendium.com/browse/fda/Ribavirin/001f213fe700c76e804c72fd47fd0c0d?reference=29,1998.0
126,209,528,Rifabutin,COC1/C=C/OC2(C)OC3=C(C2=O)C2=C(C(O)=C3C)C(O)=C(NC(=O)C(C)=CC=CC(C)C(O)C(C)C(O)C(C)C(OC(C)=O)C1C)C1=NC3(CCN(CC(C)C)CC3)N=C12,Hepatic necrosis,Mouse,-2.3010299956639813,Repeated,Oral,"FDA approval package document: Pharmacology Review 050689, page:6 PDF 2343k",https://www.pharmapendium.com/browse/fda/Rifabutin/8482c5f11425fc4dae4408390a2a35cf?reference=6,1992.0
127,210,529,Rifampin,COC1/C=C/OC2(C)OC3=C(C2=O)C2=C(C(O)=C3C)C(O)=C(NC(=O)C(C)=CC=CC(C)C(O)C(C)C(O)C(C)C(OC(C)=O)C1C)C(C=NN1CCN(C)CC1)=C2O,Hepatic necrosis,Rat,-0.3010299956639812,Repeated,Oral,Reference from PharmaPendium Published Toxicity: 607197791   ---   DOI:10.1016/j.jddst.2015.10.021   ISSN:1773-2247   JOURNAL:Journal of Drug Delivery Science and Technology Part A   PAGES:225   VOLUME:30,http://dx.doi.org/10.1016/j.jddst.2015.10.021,2015.0
128,211,530,Rifapentine,COC1/C=C/OC2(C)OC3=C(C2=O)C2=C(C(O)=C3C)C(O)=C(NC(=O)C(C)=CC=CC(C)C(O)C(C)C(O)C(C)C(OC(C)=O)C1C)C(C=NN1CCN(C3CCCC3)CC1)=C2O,Hepatic necrosis,Mouse,-1.7781512503836436,Repeated,Oral,"FDA approval package document: Approval Package 021024/S-000 Part 03, page:20 PDF 1576k",https://www.pharmapendium.com/browse/fda/Rifapentine/3571ba2cb11af6b710e653c49818811c?reference=20,1998.0
129,214,535,Risedronate Sodium,O=[PH](=O)(O)C(O)(CC1=CC=CN=C1)[PH](=O)(=O)O,Hepatic necrosis,Mouse,-1.505149978319906,Repeated,Oral,"FDA approval package document: Pharmacology Review 020835/S-001, S-004, S-003, S-002 Part 01, page:19 PDF 1964k",https://www.pharmapendium.com/browse/fda/Risedronate Sodium/3c6fee45b3564e9f3f32f4a98073a377?reference=19,1999.0
130,215,537,Ritonavir,CC(C)C1=NC(CN(C)C(=O)NC(C(=O)NC(CC2=CC=CC=C2)CC(O)C(CC2=CC=CC=C2)NC(=O)OCC2=CN=CS2)C(C)C)=CS1,Hepatic necrosis,Mouse,-2.404406050921269,Repeated,Oral,"FDA approval package document: Pharmacology Review 020659, page:24 PDF 2500k",https://www.pharmapendium.com/browse/fda/Ritonavir/73d0c1aae62a1c01de24d981e01437d9?reference=24,1995.0
131,217,542,Rofecoxib,CS(=O)(=O)C1=CC=C(C2=COC(O)=C2C2=CC=CC=C2)C=C1,Hepatic necrosis,Rat,-2.335314592824067,Repeated,Oral,"FDA approval package document: Pharmacology Review 021042/S-000; 021052/S-000 Part 06, page:4 PDF 735k",https://www.pharmapendium.com/browse/fda/Rofecoxib/e2042abc613e806e1bef353f1ecec345?reference=4,1998.0
132,218,550,Ropivacaine Hydrochloride Monohydrate,CCCN1CCCCC1C(=O)NC1=C(C)C=CC=C1C,Hepatic necrosis,Rat,-1.414973347970818,Repeated,Subcutaneous,"FDA approval package document: Pharmacology Review 020533 Part 01, page:63 PDF 2175k",https://www.pharmapendium.com/browse/fda/Ropivacaine Hydrochloride Monohydrate/c58e2f620168805b0a6bc02607b71294?reference=63,1995.0
133,222,564,Saxagliptin Hydrochloride,N#CC1CC2CC2N1C(=O)C(N)C12CC3CC(CC(O)(C3)C1)C2,Hepatic necrosis,Rat,-2.4771212547196626,Repeated,Oral,"FDA approval package document: Pharmacology Review 022350/S-000 Part 03, page:49 PDF 6472k",https://www.pharmapendium.com/browse/fda/Saxagliptin Hydrochloride/56063300b31a38ec6b2270403b6907fe?reference=49,2009.0
134,223,565,Scopolamine,CN1C2CC(OC(=O)C(CO)C3=CC=CC=C3)CC1C1OC12,Hepatic necrosis,Rat,-2.0791812460476247,Repeated,Intraperitoneal,Reference from PharmaPendium Published Toxicity: 362372038   ---   ISSN:1996-0875   JOURNAL:Journal of Medicinal Plant Research   PAGES:3421   VOLUME:5,,2011.0
135,224,566,Selexipag,CC(C)N(CCCCOCC(=O)NS(C)(=O)=O)C1=NC(C2=CC=CC=C2)=C(C2=CC=CC=C2)N=C1,Hepatic necrosis,Mouse,-2.6989700043360187,Repeated,Oral,"FDA approval package document: Pharmacology Review 207947/S-000 Part 01, page:32 PDF 13988k",https://www.pharmapendium.com/browse/fda/Selexipag/28813d88547ecbe05d7ca7b004e64861?reference=32,2010.0
136,225,567,Sildenafil Citrate,CCCC1=NN(C)C2=C1N=C(C1=CC(S(=O)(=O)N3CCN(C)CC3)=CC=C1OCC)NC2=O,Hepatic necrosis,Rabbit,-1.7906369619317033,Repeated,Intraperitoneal,Reference from PharmaPendium Published Toxicity: 607040838   ---   ISSN:1011-601X   JOURNAL:Pakistan Journal of Pharmaceutical Sciences   PAGES:2119   VOLUME:28,,2015.0
137,226,572,Simeprevir Sodium,COC1=CC=C2C(OC3CC4C(=O)NC5(C(=O)NS(=O)(=O)C6CC6)CC5/C=C\CCCCN(C)C(=O)C4C3)=CC(C3=NC(C(C)C)=CS3)=NC2=C1C,Hepatic necrosis,Rat,-2.5563025007672877,Repeated,Oral,"FDA approval package document: Pharmacology Review 205123/S-000 Part 12, page:22 PDF 4240k",https://www.pharmapendium.com/browse/fda/Simeprevir Sodium/59c278849b176a4ff667e80b2e3e3039?reference=22,2013.0
138,227,573,Simvastatin,CCC(C)(C)C(=O)OC1CC(C)C=C2C=CC(C)C(CCC3CC(O)CC(=O)O3)C21,Hepatic necrosis,Rat,-1.8044801891059927,Repeated,Oral,"FDA approval package document: Approval Package 019766/S-001, S-002, S-003, S-004, S-005, S-006; 019643/S-041, S-007, S-009, S-037, S-010, S-011, S-013, S-021, S-015 Part 03, page:11 PDF 5142k",https://www.pharmapendium.com/browse/fda/Simvastatin/4ac993ac6bc9a9f5555c1ec9ba3e3165?reference=11,1991.0
139,231,584,Sodium Nitrite,O=NO,Hepatic necrosis,Mouse,-0.9030899869919436,Repeated,Oral,Reference from PharmaPendium Published Toxicity: E-53196455   ---   DOI:10.1016/j.etp.2014.05.003   ISSN:0940-2993   JOURNAL:Experimental and Toxicologic Pathology   PAGES:367   VOLUME:66,http://dx.doi.org/10.1016/j.etp.2014.05.003,2014.0
140,232,586,Solriamfetol Hydrochloride,NC(=O)OCC(N)CC1=CC=CC=C1,Hepatic necrosis,Rat,-2.645422269349092,Repeated,Oral,"EMA approval document: Public Assessment Report EMA/686622/2019; EMEA/H/C/004893/0000, page:30 PDF 2601k",https://www.pharmapendium.com/browse/ema/Solriamfetol Hydrochloride/5f1a8c7d521a68a1b6dd499ad36bab3c?reference=30,2019.0
141,234,590,Stavudine,CC1=CN(C2C=CC(CO)O2)C(=O)NC1=O,Hepatic necrosis,Mouse,-3.3010299956639813,Repeated,Oral,"FDA approval package document: Pharmacology Review 020412, page:16 PDF 2568k",https://www.pharmapendium.com/browse/fda/Stavudine/a19d81d9163ac58f34061720ec61d707?reference=16,1994.0
142,235,595,Stiripentol,CC(C)(C)C(O)/C=C/C1=CC=C2OCOC2=C1,Hepatic necrosis,Rat,-1.9030899869919435,Repeated,Oral,"FDA approval package document: Pharmacology Review 206709/S-000; 207223/S-000 Part 02, page:34 PDF 4467k",https://www.pharmapendium.com/browse/fda/Stiripentol/83a501b83abbfc2c7987f8eb53ab65bf?reference=34,2018.0
143,236,596,Sumatriptan Succinate,CNS(=O)(=O)CC1=CC=C2NC=C(CCN(C)C)C2=C1,Hepatic necrosis,Rat,-1.5250448070368452,Repeated,Inhalation,"FDA approval package document: Approval Package 020626 Part 03, page:45 PDF 10057k",https://www.pharmapendium.com/browse/fda/Sumatriptan Succinate/fa58bff99dc92f0b99b39ee4190f1d2f?reference=45,1997.0
144,238,600,Tadalafil,CN1CC(=O)N2C(CC3=C(NC4=C3C=CC=C4)C2C2=CC=C3OCOC3=C2)C1=O,Hepatic necrosis,Mouse,-2.6020599913279625,Repeated,Oral,"FDA approval package document: Pharmacology Review 021368/S-000, page:37 PDF 3201k",https://www.pharmapendium.com/browse/fda/Tadalafil/e649398ccb9385425e1bdf5bfbe912a0?reference=37,2001.0
145,239,601,Tafamidis Meglumine,CNCC(O)C(O)C(O)C(O)CO,Hepatic necrosis,Rat,-1.0791812460476249,Repeated,Oral,"FDA approval package document: Pharmacology Review 021199/S-000, page:58 PDF 7828k",https://www.pharmapendium.com/browse/fda/Tafamidis Meglumine/545d267566ccb8c48ebf2151cded7963?reference=58,2019.0
146,241,609,Tamsulosin Hydrochloride,CCOC1=CC=CC=C1OCCNC(C)CC1=CC=C(OC)C(S(N)(=O)=O)=C1,Hepatic necrosis,Rat,-0.1760912590556812,Repeated,Oral,"FDA approval package document: Approval Package 020579/S-000, page:186 PDF 8915k",https://www.pharmapendium.com/browse/fda/Tamsulosin Hydrochloride/4d520d656e6071d5a0b8a892b782821d?reference=186,1997.0
147,242,611,Tapentadol Hydrochloride,CCC(C1=CC(O)=CC=C1)C(C)CN(C)C,Hepatic necrosis,Mouse,-2.404406050921269,Repeated,Oral,"FDA approval package document: Pharmacology Review 022304/S-000 Part 02, page:19 PDF 6376k",https://www.pharmapendium.com/browse/fda/Tapentadol Hydrochloride/0ad47c11902adf65b04e5c9c7b4f4679?reference=19,2008.0
148,243,615,Tasimelteon,CCC(=O)NCC1CC1C1=C2CCOC2=CC=C1,Hepatic necrosis,Rat,-2.544068044350276,Repeated,Oral,"FDA approval package document: Pharmacology Review 205677/S-000 Part 02, page:86 PDF 9816k",https://www.pharmapendium.com/browse/fda/Tasimelteon/a44387cf3bdf9c6066acae0b5bc5ef8b?reference=86,2014.0
149,244,618,Telithromycin,CCC1OC(=O)C(C)C(=O)C(C)C(OC2OC(C)CC(N(C)C)C2O)C(C)(OC)CC(C)C(=O)C(C)C2N(CCCCN3C=NC(C4=CN=CC=C4)=C3)C(=O)OC12C,Hepatic necrosis,Rat,-2.1760912590556813,Repeated,Oral,"FDA approval package document: Pharmacology Review 021144/S-000 Part 01, page:26 PDF 1557k",https://www.pharmapendium.com/browse/fda/Telithromycin/1bcd4775842b1ce382c420702b6762de?reference=26,2001.0
150,245,619,Telmisartan,CCCC1=NC2=C(C)C=C(C3=NC4=CC=CC=C4N3C)C=C2N1CC1=CC=C(C2=CC=CC=C2C(=O)O)C=C1,Hepatic necrosis,Mouse,-1.4771212547196624,Repeated,Oral,"FDA approval package document: Pharmacology Review 020850/S-000 Part 03, page:13 PDF 3314k",https://www.pharmapendium.com/browse/fda/Telmisartan/64977b327bddbd71ba1b83e6cba8382a?reference=13,1998.0
151,246,620,Temozolomide,CN1N=NC2=C(C(N)=O)N=CN2C1=O,Hepatic necrosis,Rat,-0.3010299956639812,Repeated,Oral,"FDA approval package document: Pharmacology Review 021029, page:35 PDF 2222k",https://www.pharmapendium.com/browse/fda/Temozolomide/7691fbb106093e0f25e9ec91b13879d4?reference=35,1999.0
152,247,621,Temsirolimus,COC1CC2CCC(C)C(O)(O2)C(=O)C(=O)N2CCCCC2C(=O)OC(C(C)CC2CCC(OC(=O)C(C)(CO)CO)C(OC)C2)CC(=O)C(C)=CC(C)C(O)C(OC)C(=O)C(C)CC(C)/C=C/C=C/C=C/1C,Hepatic necrosis,Rat,-0.0,Repeated,Oral,"FDA approval package document: Pharmacology Review 022088/S-000, page:99 PDF 8354k",https://www.pharmapendium.com/browse/fda/Temsirolimus/0183d06b6d2b5e2a1bb04cba659d9141?reference=99,2007.0
153,248,622,Tenofovir Disoproxil Fumarate,CC(C)OC(=O)OCOP(=O)(COC(C)CN1C=NC2=C1N=CN=C2N)OCOC(=O)OC(C)C,Hepatic necrosis,Mouse,-3.0,Repeated,Oral,"FDA approval package document: Pharmacology Review 021356/S-000 Part 01, page:28 PDF 1359k",https://www.pharmapendium.com/browse/fda/Tenofovir Disoproxil Fumarate/40a7be739a87c23f5677231e4fad5742?reference=28,2001.0
154,249,623,Terbinafine Hydrochloride,CN(C/C=C/C#CC(C)(C)C)CC1=C2C=CC=CC2=CC=C1,Hepatic necrosis,Rat,-1.9867717342662448,Repeated,Oral,"FDA approval package document: Pharmacology Review 022071/S-000, page:17 PDF 1948k",https://www.pharmapendium.com/browse/fda/Terbinafine Hydrochloride/e646e33ac2659654fd3742b463c0aef6?reference=17,2006.0
155,251,627,Thiabendazole,C1=CC=C2NC(C3=CSC=N3)=NC2=C1,Hepatic necrosis,Mouse,-1.1139433523068367,Repeated,Oral,"Reference from PharmaPendium Published Toxicity: Food and Chemical Toxicology 34,709,1996   ---   DOI:10.1016/0278-6915(96)00035-X   ISSN:0278-6915   JOURNAL:Food and Chemical Toxicology   PAGES:709   VOLUME:34",http://dx.doi.org/10.1016/0278-6915(96)00035-X,1996.0
156,252,628,Tiagabine Hydrochloride,CC1=C(C(=CCCN2CCCC(C(=O)O)C2)C2=C(C)C=CS2)SC=C1,Hepatic necrosis,Rat,-2.6020599913279625,Repeated,Oral,"FDA approval package document: Pharmacology Review 020646/S-000, page:66 PDF 2943k",https://www.pharmapendium.com/browse/fda/Tiagabine Hydrochloride/894610cf692f8a2e81052b07f65e96f5?reference=66,1996.0
157,253,630,Tiotropium Bromide,C[N+]1(C)C2CC(OC(=O)C(O)(C3=CC=CS3)C3=CC=CS3)CC1C1OC12,Hepatic necrosis,Mouse,-6.903089986991944,Repeated,Inhalation,"FDA approval package document: Pharmacology Review 021395/S-000 Part 02, page:32 PDF 1360k",https://www.pharmapendium.com/browse/fda/Tiotropium Bromide/95856b34671e865c9308b640c8673606?reference=32,2002.0
158,255,641,Tofacitinib Citrate,CC1CCN(C(=O)CC#N)CC1N(C)C1=C2C=CNC2=NC=N1,Hepatic necrosis,Rat,-3.0,Repeated,Oral,"FDA approval package document: Pharmacology Review 203214/S-000 Part 04, page:48 PDF 4616k",https://www.pharmapendium.com/browse/fda/Tofacitinib Citrate/daedbd7132ba97680e1b4942adc96a75?reference=48,2012.0
159,256,642,Tolmetin Sodium,CC1=CC=C(C(=O)C2=CC=C(CC(=O)O)N2C)C=C1,Hepatic necrosis,Rabbit,-1.3222192947339193,Repeated,Rectal,Reference from PharmaPendium Published Toxicity: 624704759   ---   DOI:10.1080/03639045.2018.1534858   ISSN:0363-9045   JOURNAL:Drug Development and Industrial Pharmacy   PAGES:252   VOLUME:45,http://dx.doi.org/10.1080/03639045.2018.1534858,2019.0
160,257,643,Trabectedin,COC1=C(O)C=C2CCNC3(CSC4C5=C(C6=C(OCO6)C(C)=C5OC(C)=O)C(COC3=O)N3C(O)C5CC6=C(C(O)=C(OC)C(C)=C6)C(C43)N5C)C2=C1,Hepatic necrosis,Rat,-0.3010299956639812,Repeated,Intravenous,"EMA approval document: Scientific Discussion, page:7 PDF 1081k",https://www.pharmapendium.com/browse/ema/Trabectedin/99561900e0bb277dde3f10a108ff162b?reference=7,2007.0
161,259,654,Trandolapril,CCOC(=O)C(CCC1=CC=CC=C1)NC(C)C(=O)N1C(C(=O)O)CC2CCCCC21,Hepatic necrosis,Mouse,-0.0,Repeated,Oral,"FDA approval package document: Pharmacology Review 020528 Part 02, page:44 PDF 2160k",https://www.pharmapendium.com/browse/fda/Trandolapril/1f5085202bfc658b673d03ee49fc6d7b?reference=44,1995.0
162,260,655,Tretinoin,CC(C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)=CC(=O)O,Hepatic necrosis,Mouse,-6.823908806088486,Repeated,Intravenous,Reference from PharmaPendium Published Toxicity: 630948773   ---   DOI:10.3389/fphar.2019.01676   ISSN:1663-9812   JOURNAL:Frontiers in Pharmacology   PAGES:01676   VOLUME:10,http://dx.doi.org/10.3389/fphar.2019.01676,2020.0
163,262,662,Trimethobenzamide Hydrochloride,COC1=CC(C(=O)NCC2=CC=C(OCCN(C)C)C=C2)=CC(OC)=C1OC,Hepatic necrosis,Rat,-0.6989700043360189,Repeated,Intramuscular,Reference from PharmaPendium Published Toxicity: 362549560   ---   DOI:10.3109/14767058.2010.536867   ISSN:1476-7058   JOURNAL:Journal of Maternal-Fetal and Neonatal Medicine   PAGES:1176   VOLUME:24,http://dx.doi.org/10.3109/14767058.2010.536867,2011.0
164,263,663,Troglitazone,CC1=C(O)C(C)=C2CCC(C)(COC3=CC=C(CC4=C(O)NC(=O)S4)C=C3)OC2=C1C,Hepatic necrosis,Mouse,-0.6020599913279624,Repeated,Intraperitoneal,"Reference from PharmaPendium Published Toxicity: Toxicological Sciences 97,205,2007   ---   DOI:10.1093/TOXSCI/KFL180   ISSN:1096-6080   JOURNAL:Toxicological Sciences   PAGES:205   VOLUME:97",http://dx.doi.org/10.1093/TOXSCI/KFL180,2007.0
165,264,665,Trospium Chloride,O=C(OC1CC2CCC(C1)[N+]21CCCC1)C(O)(C1=CC=CC=C1)C1=CC=CC=C1,Hepatic necrosis,Mouse,-2.3010299956639813,Repeated,Oral,"FDA approval package document: Pharmacology Review 021595/S-000, page:38 PDF 1429k",https://www.pharmapendium.com/browse/fda/Trospium Chloride/6ea28b2f40d348dd2b555b41efeeaabb?reference=38,2003.0
166,267,673,Ursodiol,CC(CCC(=O)O)C1CCC2C3C(O)CC4CC(O)CCC4(C)C3CCC12C,Hepatic necrosis,Rat,-3.051117426525757,Repeated,Intraperitoneal,"FDA approval package document: Pharmacology Review 020675/S-000 Part 06, page:7 PDF 961k",https://www.pharmapendium.com/browse/fda/Ursodiol/ef8dd1c51fb59170ae364a82e624a947?reference=7,1997.0
167,268,685,Valproate Sodium,CCCC(CCC)C(=O)O,Hepatic necrosis,Rat,-1.1760912590556811,Repeated,Intraperitoneal,Reference from PharmaPendium Published Toxicity: 621155033   ---   DOI:10.1111/nep.13012   ISSN:1320-5358   JOURNAL:Nephrology   PAGES:351   VOLUME:23,http://dx.doi.org/10.1111/nep.13012,2018.0
168,269,686,Valsartan,CCCCC(=O)N(CC1=CC=C(C2=CC=CC=C2C2=NNN=N2)C=C1)C(C(=O)O)C(C)C,Hepatic necrosis,Mouse,-2.3010299956639813,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 020665, page:16 PDF 1695k",https://www.pharmapendium.com/browse/fda/Valsartan/ccb958da9cca11b7e8c489e3e10871d1?reference=16,1995.0
169,270,687,Varenicline Tartrate,C1=CN=C2C=C3C(=CC2=N1)C1CNCC3C1,Hepatic necrosis,Mouse,-2.0,Repeated,Oral,"EMA approval document: Scientific Discussion, page:8 PDF 599k",https://www.pharmapendium.com/browse/ema/Varenicline Tartrate/e353d6847fe885598fede88591aa8c56?reference=8,2006.0
170,271,689,Vortioxetine Hydrobromide,CC1=CC(C)=C(SC2=CC=CC=C2N2CCNCC2)C=C1,Hepatic necrosis,Rat,-1.670245853074124,Repeated,Oral,"FDA approval package document: Pharmacology Review 204447/S-000 Part 01, page:38 PDF 8806k",https://www.pharmapendium.com/browse/fda/Vortioxetine Hydrobromide/e45e9e6167d7c8df7a2d36a610931d77?reference=38,2013.0
171,272,695,Zafirlukast,COC1=CC(C(=O)NS(=O)(=O)C2=CC=CC=C2C)=CC=C1CC1=CN(C)C2=C1C=C(NC(=O)OC1CCCC1)C=C2,Hepatic necrosis,Mouse,-2.740362689494244,Repeated,Oral,"FDA approval package document: Pharmacology Review 020547 Part 01, page:54 PDF 2071k",https://www.pharmapendium.com/browse/fda/Zafirlukast/bff4d77a7b86fd8ff57aa0fb26436161?reference=54,1996.0
172,273,697,Zaleplon,CCN(C(C)=O)C1=CC=CC(C2=CC=NC3=C(C#N)C=NN23)=C1,Hepatic necrosis,Mouse,-2.628388930050312,Repeated,Oral,"FDA approval package document: Pharmacology Review 020859/S-000 Part 04, page:12 PDF 1652k",https://www.pharmapendium.com/browse/fda/Zaleplon/a6e4ad838665dd61983c05ac761968f6?reference=12,
173,275,703,Zoledronic Acid,O=[PH](=O)(O)C(O)(CN1C=CN=C1)[PH](=O)(=O)O,Hepatic necrosis,Mouse,-1.548184610545108,Repeated,Oral,"FDA approval package document: Pharmacology Review 021223/S-000 Part 03, page:7 PDF 537k",https://www.pharmapendium.com/browse/fda/Zoledronic Acid/317d827e71444838d4ee998fc083ee76?reference=7,1995.0
174,276,706,Zolmitriptan,CN(C)CCC1=CNC2=C1C=C(CC1COC(=O)N1)C=C2,Hepatic necrosis,Rat,-1.3979400086720375,Repeated,Oral,"FDA approval package document: Pharmacology Review 020768/S-000 Part 01, page:40 PDF 2489k",https://www.pharmapendium.com/browse/fda/Zolmitriptan/6983d1cac9886d6886e294929ef6f103?reference=40,1997.0
